Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	aspartic-type endopeptidase activity	ERVK-8 ERVK-6 ERVK-19 ERVK-7 ERVK-25	3.20e-09	37	32	5	GO:0004190
GeneOntologyMolecularFunction	aspartic-type peptidase activity	ERVK-8 ERVK-6 ERVK-19 ERVK-7 ERVK-25	3.68e-09	38	32	5	GO:0070001
GeneOntologyMolecularFunction	RNA-DNA hybrid ribonuclease activity	ERVK-8 ERVK-6 ERVK-7	6.11e-07	11	32	3	GO:0004523
GeneOntologyMolecularFunction	RNA-directed DNA polymerase activity	ERVK-8 ERVK-6 ERVK-7	1.34e-06	14	32	3	GO:0003964
GeneOntologyMolecularFunction	nicotinic acid receptor activity	HCAR3 HCAR2	2.49e-06	2	32	2	GO:0070553
GeneOntologyMolecularFunction	RNA stem-loop binding	ERVK-8 ERVK-6 ERVK-7	4.88e-06	21	32	3	GO:0035613
GeneOntologyMolecularFunction	RNA endonuclease activity, producing 5'-phosphomonoesters	ERVK-8 ERVK-6 ERVK-7	2.80e-05	37	32	3	GO:0016891
GeneOntologyMolecularFunction	DNA polymerase activity	ERVK-8 ERVK-6 ERVK-7	3.04e-05	38	32	3	GO:0034061
GeneOntologyMolecularFunction	phosphatidylcholine transfer activity	PITPNB PITPNA	3.72e-05	6	32	2	GO:0120019
GeneOntologyMolecularFunction	endonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 5'-phosphomonoesters	ERVK-8 ERVK-6 ERVK-7	5.42e-05	46	32	3	GO:0016893
GeneOntologyMolecularFunction	phosphatidylinositol transfer activity	PITPNB PITPNA	1.36e-04	11	32	2	GO:0008526
GeneOntologyMolecularFunction	RNA endonuclease activity	ERVK-8 ERVK-6 ERVK-7	2.72e-04	79	32	3	GO:0004521
GeneOntologyMolecularFunction	phosphatidylcholine transporter activity	PITPNB PITPNA	4.64e-04	20	32	2	GO:0008525
GeneOntologyMolecularFunction	nucleotide receptor activity	HCAR3 HCAR2	5.63e-04	22	32	2	GO:0016502
GeneOntologyMolecularFunction	purinergic nucleotide receptor activity	HCAR3 HCAR2	5.63e-04	22	32	2	GO:0001614
GeneOntologyMolecularFunction	endopeptidase activity	ERVK-8 ERVK-6 ERVK-19 ERVK-7 ERVK-25	5.64e-04	430	32	5	GO:0004175
GeneOntologyMolecularFunction	phospholipid transfer activity	PITPNB PITPNA	7.89e-04	26	32	2	GO:0120014
GeneOntologyMolecularFunction	RNA nuclease activity	ERVK-8 ERVK-6 ERVK-7	1.33e-03	136	32	3	GO:0004540
GeneOntologyMolecularFunction	endonuclease activity	ERVK-8 ERVK-6 ERVK-7	1.33e-03	136	32	3	GO:0004519
GeneOntologyMolecularFunction	phosphatidylcholine binding	PITPNB PITPNA	1.35e-03	34	32	2	GO:0031210
GeneOntologyMolecularFunction	nuclear thyroid hormone receptor binding	JMJD1C MED13	1.35e-03	34	32	2	GO:0046966
GeneOntologyMolecularFunction	nucleotidyltransferase activity	ERVK-8 ERVK-6 ERVK-7	1.82e-03	152	32	3	GO:0016779
GeneOntologyMolecularFunction	quaternary ammonium group binding	PITPNB PITPNA	2.46e-03	46	32	2	GO:0050997
GeneOntologyMolecularFunction	peptidase activity	ERVK-8 ERVK-6 ERVK-19 ERVK-7 ERVK-25	3.59e-03	654	32	5	GO:0008233
GeneOntologyMolecularFunction	lipid transfer activity	PITPNB PITPNA	3.76e-03	57	32	2	GO:0120013
GeneOntologyMolecularFunction	nuclease activity	ERVK-8 ERVK-6 ERVK-7	5.92e-03	231	32	3	GO:0004518
GeneOntologyMolecularFunction	phospholipid transporter activity	PITPNB PITPNA	6.25e-03	74	32	2	GO:0005548
GeneOntologyMolecularFunction	catalytic activity, acting on DNA	ERVK-8 ERVK-6 ERVK-7	8.36e-03	262	32	3	GO:0140097
GeneOntologyMolecularFunction	syntaxin binding	VAMP1 LRRK2	8.55e-03	87	32	2	GO:0019905
GeneOntologyMolecularFunction	transition metal ion binding	ERVK-8 ERVK-6 ERVK-19 RTN4IP1 ERVK-7 CYP21A2	1.05e-02	1189	32	6	GO:0046914
GeneOntologyMolecularFunction	phospholipid binding	PITPNB TIAM1 PITPNA RPS6KC1	1.10e-02	548	32	4	GO:0005543
GeneOntologyMolecularFunction	structural molecule activity	ERVK-8 ERVK-6 ERVK-19 ERVK-7 ERVK-25	1.29e-02	891	32	5	GO:0005198
GeneOntologyMolecularFunction	zinc ion binding	ERVK-8 ERVK-6 ERVK-19 RTN4IP1 ERVK-7	1.29e-02	891	32	5	GO:0008270
GeneOntologyMolecularFunction	microtubule binding	HAUS6 TIAM1 LRRK2	1.30e-02	308	32	3	GO:0008017
GeneOntologyBiologicalProcess	DNA integration	ERVK-8 ERVK-6 ERVK-7	1.06e-06	13	33	3	GO:0015074
GeneOntologyBiologicalProcess	positive regulation of adiponectin secretion	HCAR3 HCAR2	1.49e-05	4	33	2	GO:0070165
GeneOntologyBiologicalProcess	negative regulation of lipid catabolic process	HCAR3 HCAR2 ETFBKMT	2.16e-05	34	33	3	GO:0050995
GeneOntologyBiologicalProcess	DNA synthesis involved in DNA repair	ERVK-8 ERVK-6 ERVK-7	6.14e-05	48	33	3	GO:0000731
GeneOntologyBiologicalProcess	adiponectin secretion	HCAR3 HCAR2	6.91e-05	8	33	2	GO:0070162
GeneOntologyBiologicalProcess	regulation of adiponectin secretion	HCAR3 HCAR2	6.91e-05	8	33	2	GO:0070163
GeneOntologyBiologicalProcess	anatomical structure maturation	CATSPERE MTCH1 BSPH1 FERMT1 LRRK2	2.31e-04	354	33	5	GO:0071695
GeneOntologyBiologicalProcess	regulation of lipid catabolic process	HCAR3 HCAR2 ETFBKMT	2.62e-04	78	33	3	GO:0050994
GeneOntologyBiologicalProcess	RNA-templated DNA biosynthetic process	ERVK-8 ERVK-6 ERVK-7	3.14e-04	83	33	3	GO:0006278
GeneOntologyBiologicalProcess	cell-cell fusion	ERVK-8 ERVK-6 ERVK-19	3.37e-04	85	33	3	GO:0140253
GeneOntologyBiologicalProcess	syncytium formation by plasma membrane fusion	ERVK-8 ERVK-6 ERVK-19	3.37e-04	85	33	3	GO:0000768
GeneOntologyBiologicalProcess	syncytium formation	ERVK-8 ERVK-6 ERVK-19	3.86e-04	89	33	3	GO:0006949
Domain	HCAR2/3_rcpt	HCAR3 HCAR2	2.17e-06	2	28	2	IPR028017
Domain	IP_trans	PITPNB PITPNA	2.16e-05	5	28	2	PF02121
Domain	PI_transfer	PITPNB PITPNA	3.24e-05	6	28	2	IPR001666
Domain	-	PLA2R1 BSPH1	1.67e-04	13	28	2	2.10.10.10
Domain	FN_type2_col-bd	PLA2R1 BSPH1	1.95e-04	14	28	2	IPR000562
Domain	FN2_2	PLA2R1 BSPH1	1.95e-04	14	28	2	PS51092
Domain	fn2	PLA2R1 BSPH1	1.95e-04	14	28	2	PF00040
Domain	FN2_1	PLA2R1 BSPH1	1.95e-04	14	28	2	PS00023
Domain	FN2	PLA2R1 BSPH1	1.95e-04	14	28	2	SM00059
Domain	-	PITPNB PITPNA	5.38e-04	23	28	2	3.30.530.20
Domain	START-like_dom	PITPNB PITPNA	5.38e-04	23	28	2	IPR023393
Domain	Kringle-like	PLA2R1 BSPH1	1.05e-03	32	28	2	IPR013806
Domain	-	TIAM1 MTMR10 DOK3 FERMT1	2.60e-03	391	28	4	2.30.29.30
Domain	PH_dom-like	TIAM1 MTMR10 DOK3 FERMT1	3.54e-03	426	28	4	IPR011993
Domain	PH	TIAM1 DOK3 FERMT1	4.75e-03	229	28	3	PF00169
Domain	Lectin_C	PLA2R1 KLRF2	7.00e-03	84	28	2	PF00059
Domain	CLECT	PLA2R1 KLRF2	7.00e-03	84	28	2	SM00034
Domain	C_TYPE_LECTIN_2	PLA2R1 KLRF2	7.17e-03	85	28	2	PS50041
Domain	C-type_lectin-like	PLA2R1 KLRF2	7.33e-03	86	28	2	IPR001304
Domain	PH	TIAM1 DOK3 FERMT1	8.12e-03	278	28	3	SM00233
Domain	PH_DOMAIN	TIAM1 DOK3 FERMT1	8.20e-03	279	28	3	PS50003
Domain	PH_domain	TIAM1 DOK3 FERMT1	8.28e-03	280	28	3	IPR001849
Domain	-	PLA2R1 KLRF2	9.24e-03	97	28	2	3.10.100.10
Domain	C-type_lectin-like/link	PLA2R1 KLRF2	9.61e-03	99	28	2	IPR016186
Domain	CTDL_fold	PLA2R1 KLRF2	1.12e-02	107	28	2	IPR016187
Pubmed	Quantitation of HERV-K env gene expression and splicing in human breast cancer.	ERVK-6 ERVK-19 ERVK-7	7.77e-09	5	33	3	12629516
Pubmed	A revised nomenclature for transcribed human endogenous retroviral loci.	ERVK-8 ERVK-6 ERVK-19 ERVK-7 ERVK-25	2.89e-08	94	33	5	21542922
Pubmed	Genomewide screening for fusogenic human endogenous retrovirus envelopes identifies syncytin 2, a gene conserved on primate evolution.	ERVK-8 ERVK-6 ERVK-19	1.70e-07	12	33	3	14557543
Pubmed	Cloning and expression of human cDNA encoding phosphatidylinositol transfer protein beta.	PITPNB PITPNA	8.73e-07	2	33	2	8541325
Pubmed	Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet.	HCAR3 HCAR2	8.73e-07	2	33	2	31858105
Pubmed	Deficiency of metabolite sensing receptor HCA2 impairs the salutary effect of niacin in hemorrhagic shock.	HCAR3 HCAR2	8.73e-07	2	33	2	30625381
Pubmed	Exploring the role of the metabolite-sensing receptor GPR109a in diabetic nephropathy.	HCAR3 HCAR2	8.73e-07	2	33	2	32068460
Pubmed	The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome.	HCAR3 HCAR2	8.73e-07	2	33	2	30657794
Pubmed	Activated niacin receptor HCA2 inhibits chemoattractant-mediated macrophage migration via Gβγ/PKC/ERK1/2 pathway and heterologous receptor desensitization.	HCAR3 HCAR2	8.73e-07	2	33	2	28186140
Pubmed	Phospholipid transfer proteins.	PITPNB PITPNA	8.73e-07	2	33	2	1883207
Pubmed	Ketones and pain: unexplored role of hydroxyl carboxylic acid receptor type 2 in the pathophysiology of neuropathic pain.	HCAR3 HCAR2	8.73e-07	2	33	2	30085883
Pubmed	Nicotinic acid receptor abnormalities in human skin cancer: implications for a role in epidermal differentiation.	HCAR3 HCAR2	8.73e-07	2	33	2	21655214
Pubmed	Melatonin alleviates titanium nanoparticles induced osteolysis via activation of butyrate/GPR109A signaling pathway.	HCAR3 HCAR2	8.73e-07	2	33	2	34092246
Pubmed	The Immunometabolomic Interface Receptor Hydroxycarboxylic Acid Receptor 2 Mediates the Therapeutic Effects of Dimethyl Fumarate in Autoantibody-Induced Skin Inflammation.	HCAR3 HCAR2	8.73e-07	2	33	2	30154797
Pubmed	(D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G.	HCAR3 HCAR2	8.73e-07	2	33	2	15929991
Pubmed	The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival.	HCAR3 HCAR2	8.73e-07	2	33	2	24371223
Pubmed	High dietary niacin may increase prostaglandin formation but does not increase tumor formation in ApcMin/+ mice.	HCAR3 HCAR2	8.73e-07	2	33	2	21774590
Pubmed	Activation of HCA2 regulates microglial responses to alleviate neurodegeneration in LPS-induced in vivo and in vitro models.	HCAR3 HCAR2	8.73e-07	2	33	2	36991440
Pubmed	Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages.	HCAR3 HCAR2	8.73e-07	2	33	2	25320346
Pubmed	Molecular identification of high and low affinity receptors for nicotinic acid.	HCAR3 HCAR2	8.73e-07	2	33	2	12522134
Pubmed	The role of HCA2 (GPR109A) in regulating macrophage function.	HCAR3 HCAR2	8.73e-07	2	33	2	23882124
Pubmed	Crosstalk between microbiome, regulatory T cells and HCA2 orchestrates the inflammatory response in a murine psoriasis model.	HCAR3 HCAR2	8.73e-07	2	33	2	36891315
Pubmed	Nicotinic acid inhibits glucose-stimulated insulin secretion via the G protein-coupled receptor PUMA-G in murine islet β cells.	HCAR3 HCAR2	8.73e-07	2	33	2	21441844
Pubmed	Dynamics of lipid transfer by phosphatidylinositol transfer proteins in cells.	PITPNB PITPNA	8.73e-07	2	33	2	18636990
Pubmed	GPR109a Regulates Phenotypic and Functional Alterations in Macrophages and the Progression of Type 1 Diabetes.	HCAR3 HCAR2	8.73e-07	2	33	2	36208084
Pubmed	G Protein-Coupled Receptor 109A and Host Microbiota Modulate Intestinal Epithelial Integrity During Sepsis.	HCAR3 HCAR2	8.73e-07	2	33	2	30271409
Pubmed	Parabacteroides distasonis ameliorates insulin resistance via activation of intestinal GPR109a.	HCAR3 HCAR2	8.73e-07	2	33	2	38007572
Pubmed	The role of the C-terminus of the human hydroxycarboxylic acid receptors 2 and 3 in G protein activation using Gα-engineered yeast cells.	HCAR3 HCAR2	8.73e-07	2	33	2	26656756
Pubmed	Niacin fine-tunes energy homeostasis through canonical GPR109A signaling.	HCAR3 HCAR2	8.73e-07	2	33	2	30596513
Pubmed	The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimer's disease.	HCAR3 HCAR2	8.73e-07	2	33	2	35320002
Pubmed	Biased allosteric activation of ketone body receptor HCAR2 suppresses inflammation.	HCAR3 HCAR2	8.73e-07	2	33	2	37597514
Pubmed	Biochemical and biological functions of class I phosphatidylinositol transfer proteins.	PITPNB PITPNA	8.73e-07	2	33	2	17490911
Pubmed	GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.	HCAR3 HCAR2	8.73e-07	2	33	2	16322797
Pubmed	The Role of GPR109a Signaling in Niacin Induced Effects on Fed and Fasted Hepatic Metabolism.	HCAR3 HCAR2	8.73e-07	2	33	2	33924461
Pubmed	Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.	HCAR3 HCAR2	8.73e-07	2	33	2	24691444
Pubmed	BHBA treatment improves cognitive function by targeting pleiotropic mechanisms in transgenic mouse model of Alzheimer's disease.	HCAR3 HCAR2	8.73e-07	2	33	2	31914599
Pubmed	Ketone Body 3-Hydroxybutyrate Ameliorates Atherosclerosis via Receptor Gpr109a-Mediated Calcium Influx.	HCAR3 HCAR2	8.73e-07	2	33	2	33977048
Pubmed	Butyrate ameliorates caerulein-induced acute pancreatitis and associated intestinal injury by tissue-specific mechanisms.	HCAR3 HCAR2	8.73e-07	2	33	2	31347703
Pubmed	Nicotinic acid receptor agonists.	HCAR3 HCAR2	8.73e-07	2	33	2	18983141
Pubmed	Gut microbial metabolite butyrate protects against proteinuric kidney disease through epigenetic- and GPR109a-mediated mechanisms.	HCAR3 HCAR2	8.73e-07	2	33	2	31366236
Pubmed	PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily.	HCAR3 HCAR2	8.73e-07	2	33	2	11745392
Pubmed	Loss of GPR109A/HCAR2 induces aging-associated hepatic steatosis.	HCAR3 HCAR2	8.73e-07	2	33	2	30659164
Pubmed	Specific and nonspecific membrane-binding determinants cooperate in targeting phosphatidylinositol transfer protein beta-isoform to the mammalian trans-Golgi network.	PITPNB PITPNA	8.73e-07	2	33	2	16540520
Pubmed	Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets.	HCAR3 HCAR2	8.73e-07	2	33	2	25622782
Pubmed	Biological functions of phosphatidylinositol transfer proteins.	PITPNB PITPNA	8.73e-07	2	33	2	15052341
Pubmed	Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.	HCAR3 HCAR2	8.73e-07	2	33	2	20655299
Pubmed	Evidence for constitutive dimerization of niacin receptor subtypes.	HCAR3 HCAR2	8.73e-07	2	33	2	20380810
Pubmed	GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice.	HCAR3 HCAR2	8.73e-07	2	33	2	33420329
Pubmed	Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium.	HCAR3 HCAR2	8.73e-07	2	33	2	19223991
Pubmed	GPR109A Expression in the Murine Min6 Pancreatic Beta Cell Line, and Its Relation with Glucose Metabolism and Inflammation.	HCAR3 HCAR2	8.73e-07	2	33	2	26116596
Pubmed	Expression of human endogenous retrovirus type K envelope glycoprotein in insect and mammalian cells.	ERVK-6 ERVK-19	8.73e-07	2	33	2	9060628
Pubmed	Expression and activation of the ketone body receptor HCAR2/GPR109A promotes preservation of retinal endothelial cell barrier function.	HCAR3 HCAR2	8.73e-07	2	33	2	35649469
Pubmed	Molecular identification of nicotinic acid receptor.	HCAR3 HCAR2	8.73e-07	2	33	2	12646212
Pubmed	GPR109A expressed on medullary thymic epithelial cells affects thymic Treg development.	HCAR3 HCAR2	8.73e-07	2	33	2	37595951
Pubmed	PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect.	HCAR3 HCAR2	8.73e-07	2	33	2	12563315
Pubmed	The hypophagic response to heat stress is not mediated by GPR109A or peripheral β-OH butyrate.	HCAR3 HCAR2	8.73e-07	2	33	2	26936786
Pubmed	Hydroxycarboxylic Acid Receptor 2, a Pleiotropically Linked Receptor for the Multiple Sclerosis Drug, Monomethyl Fumarate. Possible Implications for the Inflammatory Response.	HCAR3 HCAR2	8.73e-07	2	33	2	34084164
Pubmed	Niacin increases adiponectin and decreases adipose tissue inflammation in high fat diet-fed mice.	HCAR3 HCAR2	8.73e-07	2	33	2	23967184
Pubmed	GPR109A gene deletion ameliorates gonadectomy-induced bone loss in mice.	HCAR3 HCAR2	8.73e-07	2	33	2	35489706
Pubmed	Evolutionary relationships within a subgroup of HERV-K-related human endogenous retroviruses.	ERVK-6 ERVK-19	8.73e-07	2	33	2	9460924
Pubmed	Involvement of the Niacin Receptor GPR109a in the LocalControl of Glucose Uptake in Small Intestine of Type 2Diabetic Mice.	HCAR3 HCAR2	8.73e-07	2	33	2	26371038
Pubmed	Structure of PITPbeta in complex with phosphatidylcholine: comparison of structure and lipid transfer to other PITP isoforms.	PITPNB PITPNA	8.73e-07	2	33	2	16274224
Pubmed	Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host disease.	HCAR3 HCAR2	8.73e-07	2	33	2	34653248
Pubmed	Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G).	HCAR3 HCAR2	8.73e-07	2	33	2	19136666
Pubmed	Genetic ablation of phosphatidylinositol transfer protein function in murine embryonic stem cells.	PITPNB PITPNA	8.73e-07	2	33	2	11907258
Pubmed	G Protein-Coupled Receptor 109A Maintains the Intestinal Integrity and Protects Against ETEC Mucosal Infection by Promoting IgA Secretion.	HCAR3 HCAR2	8.73e-07	2	33	2	33488584
Pubmed	An isoform of the phosphatidylinositol-transfer protein transfers sphingomyelin and is associated with the Golgi system.	PITPNB PITPNA	8.73e-07	2	33	2	7654206
Pubmed	Lactate-induced activation of HCA2 improves survival in mice with sepsis.	HCAR3 HCAR2	8.73e-07	2	33	2	30951370
Pubmed	Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis.	HCAR3 HCAR2	8.73e-07	2	33	2	19561068
Pubmed	The β-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages.	HCAR3 HCAR2	2.62e-06	3	33	2	24845831
Pubmed	Hyperhomocysteinemia is detrimental to pregnancy in mice and is associated with preterm birth.	HCAR3 HCAR2	2.62e-06	3	33	2	23579073
Pubmed	Short-chain fatty acids directly exert anti-inflammatory responses in podocytes and tubular epithelial cells exposed to high glucose.	HCAR3 HCAR2	2.62e-06	3	33	2	37215085
Pubmed	Oral Dimethyl Fumarate Targets HCA2-Expressing Skin Cells in the Imiquimod Mouse Model.	HCAR3 HCAR2	2.62e-06	3	33	2	35189149
Pubmed	Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8.	HCAR3 HCAR2	2.62e-06	3	33	2	20033346
Pubmed	The Butyrate-Producing Bacterium Clostridium butyricum Suppresses Clostridioides difficile Infection via Neutrophil- and Antimicrobial Cytokine-Dependent but GPR43/109a-Independent Mechanisms.	HCAR3 HCAR2	2.62e-06	3	33	2	33597149
Pubmed	Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells.	HCAR3 HCAR2	2.62e-06	3	33	2	17008386
Pubmed	Effects of high fat diet on GPR109A and GPR81 gene expression.	HCAR3 HCAR2	2.62e-06	3	33	2	22842580
Pubmed	Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.	HCAR3 HCAR2	2.62e-06	3	33	2	22914621
Pubmed	Niacin protects against abdominal aortic aneurysm formation via GPR109A independent mechanisms: role of NAD+/nicotinamide.	HCAR3 HCAR2	2.62e-06	3	33	2	31710686
Pubmed	Niacin stimulates adiponectin secretion through the GPR109A receptor.	HCAR3 HCAR2	2.62e-06	3	33	2	19141678
Pubmed	Deficiency of Prebiotic Fiber and Insufficient Signaling Through Gut Metabolite-Sensing Receptors Leads to Cardiovascular Disease.	HCAR3 HCAR2	2.62e-06	3	33	2	32093510
Pubmed	International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B).	HCAR3 HCAR2	2.62e-06	3	33	2	21454438
Pubmed	Rare and potentially pathogenic variants in hydroxycarboxylic acid receptor genes identified in breast cancer cases.	HCAR3 HCAR2	2.62e-06	3	33	2	34852802
Pubmed	Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice.	HCAR3 HCAR2	2.62e-06	3	33	2	20664170
Pubmed	Genome-wide screening, cloning, chromosomal assignment, and expression of full-length human endogenous retrovirus type K.	ERVK-6 ERVK-19	2.62e-06	3	33	2	10516026
Pubmed	The anti-apoptotic activity associated with phosphatidylinositol transfer protein alpha activates the MAPK and Akt/PKB pathway.	PITPNB PITPNA	2.62e-06	3	33	2	18501717
Pubmed	Phosphatidylinositol transfer proteins regulate megakaryocyte TGF-β1 secretion and hematopoiesis in mice.	PITPNB PITPNA	2.62e-06	3	33	2	30042096
Pubmed	Dietary Fiber Protects against Diabetic Nephropathy through Short-Chain Fatty Acid-Mediated Activation of G Protein-Coupled Receptors GPR43 and GPR109A.	HCAR3 HCAR2	2.62e-06	3	33	2	32358041
Pubmed	Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation.	HCAR3 HCAR2	2.62e-06	3	33	2	24226773
Pubmed	Activation of microglial GPR109A alleviates thermal hyperalgesia in female lupus mice by suppressing IL-18 and glutamatergic synaptic activity.	HCAR3 HCAR2	2.62e-06	3	33	2	34919284
Pubmed	Induction of the cystine/glutamate exchanger SLC7A11 in retinal pigment epithelial cells by the antipsoriatic drug monomethylfumarate.	HCAR3 HCAR2	2.62e-06	3	33	2	23404113
Pubmed	Niacin receptor GPR109A inhibits insulin secretion and is down-regulated in type 2 diabetic islet beta-cells.	HCAR3 HCAR2	2.62e-06	3	33	2	27570060
Pubmed	Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.	HCAR3 HCAR2	2.62e-06	3	33	2	21317532
Pubmed	Clostridium butyricum upregulates GPR109A/AMPK/PGC-1α and ameliorates acute pancreatitis-associated intestinal barrier injury in mice.	HCAR3 HCAR2	5.23e-06	4	33	2	38761195
Pubmed	Cloning and characterization of a novel human phosphatidylinositol transfer protein, rdgBbeta.	PITPNB PITPNA	5.23e-06	4	33	2	10531358
Pubmed	Dietary Fiber and Bacterial SCFA Enhance Oral Tolerance and Protect against Food Allergy through Diverse Cellular Pathways.	HCAR3 HCAR2	5.23e-06	4	33	2	27332875
Pubmed	Phosphatidylinositol transfer protein, cytoplasmic 1 (PITPNC1) binds and transfers phosphatidic acid.	PITPNB PITPNA	5.23e-06	4	33	2	22822086
Pubmed	Niacin activates the PI3K/Akt cascade via PKC- and EGFR-transactivation-dependent pathways through hydroxyl-carboxylic acid receptor 2.	HCAR3 HCAR2	5.23e-06	4	33	2	25375133
Pubmed	Gpr109a Limits Microbiota-Induced IL-23 Production To Constrain ILC3-Mediated Colonic Inflammation.	HCAR3 HCAR2	5.23e-06	4	33	2	29514953
Pubmed	Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas.	ERVK-6 ERVK-19	5.23e-06	4	33	2	7983737
Cytoband	12q24.31	HCAR3 HCAR2	1.44e-03	80	32	2	12q24.31
GeneFamily	Hydroxy-carboxylic acid receptors	HCAR3 HCAR2	4.24e-06	3	22	2	200
GeneFamily	Phosphatidylinositol transfer proteins	PITPNB PITPNA	2.11e-05	6	22	2	1151
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	TIAM1 FERMT1	2.57e-02	206	22	2	682
ToppCell	PBMC-Severe-Myeloid-Neutrophil-Neutrophil-Neu_0\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	HCAR3 HCAR2 JMJD1C ALPL LRRK2	1.07e-07	187	28	5	75bc05a0ba2727fecc236903ace792a28f3d3c9a
ToppCell	PBMC-Severe-Myeloid-Neutrophil-Neutrophil-Neu_0\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	HCAR3 HCAR2 JMJD1C ALPL LRRK2	1.07e-07	187	28	5	a0d59bf1043ff5a1e8110b39ecc2d3932675edd4
ToppCell	mild-Lymphocytic-CD4_T_cells_2\|Lymphocytic / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	HCAR3 HCAR2 ALPL DOK3 LRRK2	1.22e-07	192	28	5	4cd8f572e067bf5fe22f62fa868d7d332f097a8c
ToppCell	COVID-19_Severe-Neu_0\|COVID-19_Severe / 5 Neutrophil clusters in COVID-19 patients	HCAR3 HCAR2 JMJD1C ALPL LRRK2	1.35e-07	196	28	5	4831243fcd680cf4821fa0246e758c3e7c13a962
ToppCell	mild-Myeloid-Neutrophils_4\|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	HCAR3 HCAR2 ALPL DOK3 LRRK2	1.35e-07	196	28	5	f8c98cded5550843322b1711e1a57c7e88cae861
ToppCell	BL-critical-LOC-Myeloid-Neutrophil\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	HCAR3 HCAR2 ALPL DOK3 LRRK2	1.35e-07	196	28	5	f64d7fed31e418c55fe946744d78c3cbecec9bbf
ToppCell	COVID-19_Severe-Neu_0\|World / 5 Neutrophil clusters in COVID-19 patients	HCAR3 HCAR2 JMJD1C ALPL LRRK2	1.35e-07	196	28	5	4fdea41ac7d84f0c52d102d87a5fce620480985e
ToppCell	critical-Myeloid-Neutrophil\|Myeloid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	HCAR3 HCAR2 JMJD1C ALPL LRRK2	1.39e-07	197	28	5	f1248781e71e3a158d06e9ec93eb90dc6d48bcb2
ToppCell	moderate-Myeloid-Neutrophil\|Myeloid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	HCAR3 HCAR2 JMJD1C ALPL LRRK2	1.42e-07	198	28	5	a6306dac34af5783f3a734ef1eaa7a0c03267b4f
ToppCell	E16.5-Immune-Immune_Myeloid-Granulocytic-Neutrophil-Neutrophil_mature\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MTMR10 DOK3 LRRK2 RPS6KC1	2.47e-06	153	28	4	6a2a2379238133ce0ad714af130ffe02dd317247
ToppCell	E16.5-Immune-Immune_Myeloid-Granulocytic-Neutrophil\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MTMR10 DOK3 LRRK2 RPS6KC1	2.47e-06	153	28	4	faa442dd925b2b09919e93c492ccc3f19803ad24
ToppCell	Influenza_Severe-Neutrophil\|World / Disease group and Cell class	HCAR3 HCAR2 ALPL LRRK2	3.67e-06	169	28	4	6e8e2580e19c96bcf7fa6a6d8c183df65f428396
ToppCell	CTRL-Myeloid-Neutrophil\|Myeloid / Disease state, Lineage and Cell class	HCAR3 HCAR2 ALPL LRRK2	3.75e-06	170	28	4	151dabe1d240dde414c881bf4fa816c69fa1c32d
ToppCell	CTRL-Myeloid-Neutrophil\|CTRL / Disease state, Lineage and Cell class	HCAR3 HCAR2 ALPL LRRK2	3.93e-06	172	28	4	ef3a6fe3b7300959f9f71130200c7fb8741c42b0
ToppCell	severe_influenza-Neutrophil\|World / disease group, cell group and cell class (v2)	HCAR3 HCAR2 ALPL LRRK2	4.12e-06	174	28	4	f9f07436b7d3f190800cd85d229f007032f391e1
ToppCell	facs-Lung-3m-Epithelial-airway_epithelial-respiratory_basal_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	HCAR2 PIGR ALPL FERMT1	4.50e-06	178	28	4	fb8f8d95f6b08378fb42c4076ee040276faa296f
ToppCell	facs-Lung-3m-Epithelial-airway_epithelial-respiratory_basal_cell-basal_epithelial_cell_of_bronchioalveolar_tree\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	HCAR2 PIGR ALPL FERMT1	4.50e-06	178	28	4	b89c4d015b44bf538aa39969ef8778877c8023f1
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Granulocytic-Neutrophil-Neu_c4-RSAD2\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	HCAR2 ALPL DOK3 LRRK2	4.50e-06	178	28	4	94a86f5232fffa6a92a30ea21fb44eec33b4d6c8
ToppCell	COVID-19_Severe-Neutrophil-\|COVID-19_Severe / Disease condition and Cell class	HCAR3 HCAR2 ALPL LRRK2	4.81e-06	181	28	4	5e5101195d5ff8c8ea7ddcf0bc4f4e03e64c01e0
ToppCell	droplet-Marrow-BM-1m-Myeloid-nan\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MTCH1 ALPL PITPNA DOK3	4.81e-06	181	28	4	89c551de26de047c316c91ac1d97bdf728a33d9e
ToppCell	COVID-19_Severe-Neutrophil\|COVID-19_Severe / Disease condition and Cell class	HCAR3 HCAR2 ALPL LRRK2	4.81e-06	181	28	4	aa5e5fb0308b5e2ef918548c85529c9a433c57f5
ToppCell	droplet-Marrow-BM-1m-Myeloid\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MTCH1 ALPL PITPNA DOK3	5.13e-06	184	28	4	69348c9237e44f7752ac01f60e733ad41580fdb8
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_INF-D\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	HCAR3 HCAR2 PIGR VAMP1	5.59e-06	188	28	4	e32d95f8e86111245d7f4b5fd72d2471fe0f1304
ToppCell	COVID-19_Severe-Myeloid_G-Neutrophil\|COVID-19_Severe / Disease group, lineage and cell class	HCAR3 HCAR2 ALPL LRRK2	5.71e-06	189	28	4	a62f4c445ede00d15b74bee65f4e4fb54cfd4d32
ToppCell	PBMC-Severe-Myeloid-Neutrophil-Neutrophil\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	HCAR3 HCAR2 ALPL LRRK2	5.71e-06	189	28	4	f6b2b4824505f0119a017fdb73c55418fb651645
ToppCell	PBMC-Severe-Myeloid-Neutrophil-Neutrophil\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	HCAR3 HCAR2 ALPL LRRK2	5.71e-06	189	28	4	db8e314ce95c32542bb4015a77032a33211fea0b
ToppCell	10x_3'_v3-lymph_node_(10x_3'_v3)-myeloid-myeloid_granulocytic-neutrophil\|lymph_node_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	HCAR3 HCAR2 ALPL LRRK2	5.71e-06	189	28	4	235c24eeab5139f5821fccd5c879d8787682f4ef
ToppCell	PBMC-Severe-Myeloid-Neutrophil\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	HCAR3 HCAR2 ALPL LRRK2	5.83e-06	190	28	4	cb62ece5929896dfba30a4f563c6ba5a5712b71e
ToppCell	PBMC-Severe-Myeloid-Neutrophil\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	HCAR3 HCAR2 ALPL LRRK2	5.83e-06	190	28	4	fedd266198d294d8da8c9e217e5e0cb8b2e1b566
ToppCell	wk_20-22-Hematologic-Myeloid-Neutrophil\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	HCAR3 HCAR2 ALPL LRRK2	5.83e-06	190	28	4	5da4a90f56f66567614d84b9b437f559006ea51c
ToppCell	COVID-19_Severe-Myeloid_G\|COVID-19_Severe / Disease group, lineage and cell class	HCAR3 HCAR2 ALPL LRRK2	5.83e-06	190	28	4	8a81cb90273c361e9fdfaa0a31806da253fa1388
ToppCell	saliva-Mild-Moderate_progression_d12-25-Myeloid-Monocytic-Classical_Monocyte-Mono_c3-CD14-VCAN\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	HCAR2 JMJD1C ALPL LRRK2	5.95e-06	191	28	4	47156e5f1d790707f42f6283104a44b33af613e5
ToppCell	NS-critical-d_0-4-Myeloid-Neutrophil\|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	HCAR3 HCAR2 ALPL LRRK2	6.07e-06	192	28	4	3db74359c30172a51177e00eac1f48f483e15578
ToppCell	mild-Myeloid-Neutrophils_1\|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	HCAR3 ALPL DOK3 LRRK2	6.33e-06	194	28	4	ccd911ce3251cd1c60f1fb2ce00650fbe7a379bb
ToppCell	saliva-Severe-critical_progression_d28-40-Myeloid-Granulocytic\|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)	HCAR2 JMJD1C DOK3 LRRK2	6.33e-06	194	28	4	607b5d194ba56efa9b106f10f89368fc103712a0
ToppCell	saliva-Severe-critical_progression_d28-40-Myeloid-Granulocytic-Neutrophil\|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)	HCAR2 JMJD1C DOK3 LRRK2	6.33e-06	194	28	4	f5367072b259ae170cf0df3d4d871ab41be29d29
ToppCell	control-Lymphocytic-CD4_T_cells_2\|Lymphocytic / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	HCAR3 ALPL DOK3 LRRK2	6.33e-06	194	28	4	c2ae2ea848d78725455dcb6be9f1d8933745fa80
ToppCell	saliva-Mild-Moderate_progression_d12-25-Myeloid-Granulocytic-Neutrophil\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	HCAR2 JMJD1C ALPL LRRK2	6.59e-06	196	28	4	fe8d3f45a64323947c36b127355d5940eb56c0ca
ToppCell	NS-moderate-d_16-33-Myeloid\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	HCAR3 HCAR2 DOK3 LRRK2	6.59e-06	196	28	4	dc8483625f1188771eb98bd94757b25163b2fc2f
ToppCell	saliva-Mild-Moderate_progression_d12-25-Myeloid-Granulocytic\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	HCAR2 JMJD1C ALPL LRRK2	6.59e-06	196	28	4	526d037bb12d81f1c235c60ddc787fbad0bbad77
ToppCell	control-Myeloid-Non-resident_Macrophage\|Myeloid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	TIAM1 MTCH1 JMJD1C LRRK2	6.72e-06	197	28	4	df2fe36cb96e2565a9d21c24cb4e451e8befd4be
ToppCell	saliva-Severe-critical_progression_d28-40-Myeloid-Granulocytic-Neutrophil-Neu_c1-IL1B\|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)	HCAR2 ALPL DOK3 LRRK2	6.72e-06	197	28	4	340ce4fef244176fb52e38ffbcbdfda5ac3467dd
ToppCell	BL-critical-LOC-Myeloid\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	HCAR3 ALPL DOK3 LRRK2	6.72e-06	197	28	4	932a7fae4979b561688e6222505df0f4e510ab11
ToppCell	saliva-Mild-Moderate_progression_d12-25-Myeloid-Granulocytic-Neutrophil-Neu_c1-IL1B\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	HCAR2 JMJD1C ALPL LRRK2	6.72e-06	197	28	4	3cd1c816bc7a57278b2ef615b69545356ab8f522
ToppCell	NS-critical-d_07-13-Myeloid-Neutrophil\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	HCAR3 HCAR2 DOK3 LRRK2	6.72e-06	197	28	4	f38037dfa6c33e9336130d0cc65eaba0f120efb9
ToppCell	Control-Control-Myeloid-Neutrophil\|Control / Disease, condition lineage and cell class	PLA2R1 HCAR2 JMJD1C LRRK2	7.14e-06	200	28	4	95c41f147a1594d49e73cb56d86d301c3115ce20
ToppCell	severe-Neutrophil\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	HCAR3 HCAR2 ALPL LRRK2	7.14e-06	200	28	4	f04d5951bac4dee47c22aaf7973312ca797f322e
ToppCell	severe-Neutrophil\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	HCAR3 HCAR2 ALPL LRRK2	7.14e-06	200	28	4	f9af7e77a8483ab4ae708b55514e64f5420fa0c1
ToppCell	PBMC-Mild-Myeloid-Neutrophil-Neutrophil-Neu_1\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	HCAR2 ALPL LRRK2	5.35e-05	117	28	3	3d98d77b4725d684e7496059e8b0ffffbe40301d
ToppCell	PBMC-Mild-Myeloid-Neutrophil-Neutrophil-Neu_1\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	HCAR2 ALPL LRRK2	5.35e-05	117	28	3	089793a950e8593b4acc1ba6a5e5474682f5fda6
ToppCell	PBMC-Mild-Myeloid-Neutrophil-Neutrophil\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	HCAR2 ALPL LRRK2	6.67e-05	126	28	3	ec32bfd6cd93fbe02f7577893c82b04d209a52e7
ToppCell	PBMC-Mild-Myeloid-Neutrophil-Neutrophil\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	HCAR2 ALPL LRRK2	8.01e-05	134	28	3	7b237690a3765d974f6f813ef2d01154bc23b9d6
ToppCell	COVID-19_Mild-Myeloid_G-Neutrophil\|COVID-19_Mild / Disease group, lineage and cell class	HCAR2 ALPL LRRK2	8.19e-05	135	28	3	e9eb2bebb6d19c439c83f46c12ca0d676db69de8
ToppCell	PBMC-Severe-Myeloid-Neutrophil-Neutrophil-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	HCAR3 HCAR2 ALPL	8.93e-05	139	28	3	fa0eedebf53317928022c3bed391ce99a2114f98
ToppCell	COVID-19_Mild-Myeloid_G\|COVID-19_Mild / Disease group, lineage and cell class	HCAR2 ALPL LRRK2	9.52e-05	142	28	3	c8aeb747ed836197265d269aa131fae172b45aec
ToppCell	PBMC-Mild-Myeloid-Neutrophil\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	HCAR2 ALPL LRRK2	9.72e-05	143	28	3	974260c25dad599eea83a33e83117f7307b92a42
ToppCell	5'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	HCAR2 PIGR CYP21A2	1.19e-04	153	28	3	3240d4d690335ba22317b1f3d33f9ea069e93838
ToppCell	5'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	HCAR2 PIGR CYP21A2	1.19e-04	153	28	3	edf5d026e8e4c685b7c369d70894741bb2cd568e
ToppCell	390C-Epithelial_cells-Epithelial-A_(AT2)\|390C / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.35e-04	160	28	3	731def6d82814ebac1a400bc7aea5f6da43ec960
ToppCell	367C-Epithelial_cells-Epithelial-D_(AT2)-\|367C / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.35e-04	160	28	3	b81d218c20fe37921cf3c6c7db2da3bfd367230a
ToppCell	390C-Epithelial_cells-Epithelial-A_(AT2)-\|390C / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.35e-04	160	28	3	cf27b4ac4d0caa6f9b068dc8ea93472470a01a4d
ToppCell	367C-Epithelial_cells-Epithelial-D_(AT2)\|367C / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.35e-04	160	28	3	ac5d573c135d66d6adddd42dfddd9d3e01532172
ToppCell	droplet-Lung-immune-endo-depleted-3m-Lymphocytic-Zbtb32+_B\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RTN4IP1 PIGR ALPL	1.38e-04	161	28	3	249c2b97cc25de5053f5048ee354615df49b2081
ToppCell	3'_v3-GI_small-bowel-Lymphocytic_T_CD8-Tem/emra_CD8\|GI_small-bowel / Manually curated celltypes from each tissue	PLA2R1 PIGR ALPL	1.43e-04	163	28	3	1a8c79903ed416f286ebe8a9922233affbc55d82
ToppCell	367C-Epithelial_cells-Epithelial-A_(AT2)\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.46e-04	164	28	3	b0ed8cb6000ce8bf94444307e4b7b3574fa3fab2
ToppCell	368C-Epithelial_cells-Epithelial-A_(AT2)-\|368C / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.46e-04	164	28	3	85f53d184fa70e3eb1af655807f32b17ddbfb304
ToppCell	343B-Epithelial_cells-Epithelial-A_(AT2)-\|343B / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.46e-04	164	28	3	beaa13a75c3bb72446c85084d75e9fe3f15fd3d4
ToppCell	367C-Epithelial_cells-Epithelial-A_(AT2)-\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.46e-04	164	28	3	3aea6207a011ad55a1aeb2ed9fb54d31b23694b5
ToppCell	368C-Epithelial_cells-Epithelial-A_(AT2)\|368C / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.46e-04	164	28	3	144ba070a1ede71684224cc6d4ead3b7e6a7b4c6
ToppCell	343B-Epithelial_cells-Epithelial-A_(AT2)\|343B / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.46e-04	164	28	3	d005cfd821b87548b075120bffe65a0be9860463
ToppCell	367C-Epithelial_cells-Epithelial-B_(AT2)\|367C / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.56e-04	168	28	3	e20e1936573fdde78426d7a4eb45c458d5c4dbb4
ToppCell	367C-Epithelial_cells-Epithelial-B_(AT2)-\|367C / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.56e-04	168	28	3	16b517e3159ad6e6d25fd48f7d5f46e77b2b318d
ToppCell	5'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-bronchial_goblet_cell-Goblet_(bronchial)-Goblet_(bronchial)_L.0.4.2.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PIGR CYP21A2 ALPL	1.59e-04	169	28	3	db73dae011ff3749b3706e50ab46d03b775dd6bb
ToppCell	5'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-bronchial_goblet_cell-Goblet_(bronchial)\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PIGR CYP21A2 ALPL	1.59e-04	169	28	3	97b7047b87ce0052d8580565c9b44fd2aa6f0d5c
ToppCell	5'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-bronchial_goblet_cell\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PIGR CYP21A2 ALPL	1.59e-04	169	28	3	1a684471dbda42e1470e5a889648666e14f25982
ToppCell	severe_COVID-19-Neutrophil\|World / disease group, cell group and cell class (v2)	HCAR3 HCAR2 ALPL	1.62e-04	170	28	3	dfc807e0dd66179490a258ecbe8eb439e715799d
ToppCell	droplet-Lung-nan-18m-Epithelial-Club_Cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PIGR ALPL FERMT1	1.65e-04	171	28	3	3b02dc5609f5bcd055b532bb4631d2a7183804e9
ToppCell	droplet-Lung-nan-18m-Epithelial-club_cell_of_bronchiole\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PIGR ALPL FERMT1	1.65e-04	171	28	3	88309bfb1cf427783c853dfd6709cd5edc9074b9
ToppCell	10x5'-Lung-Myeloid_Mac-Erythrophagocytic_macrophages\|Lung / Manually curated celltypes from each tissue	PLA2R1 ALPL FERMT1	1.68e-04	172	28	3	075b33b41c521fe2bba567878c68d86f452af680
ToppCell	severe_COVID-19-Neutrophil\|severe_COVID-19 / disease group, cell group and cell class (v2)	HCAR3 HCAR2 ALPL	1.68e-04	172	28	3	8f4bcb9b2bbf8b4333f673d8ad6bb88dfda4792a
ToppCell	BAL-Severe-Myeloid-Neutrophil-Neutrophil-Neu_3\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	HCAR3 HCAR2 ALPL	1.71e-04	173	28	3	1edef5aeab626cbf2c09468e77b02cfa2d21ba03
ToppCell	BAL-Severe-Myeloid-Neutrophil-Neutrophil\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	HCAR3 HCAR2 ALPL	1.71e-04	173	28	3	c37dba3804df7c3151e18e6ae4e0b6e7a92bae97
ToppCell	BAL-Severe-Myeloid-Neutrophil\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	HCAR3 HCAR2 ALPL	1.71e-04	173	28	3	5b76d9cc56bbb29017e64a2d0a3c76c0be003d96
ToppCell	BAL-Severe-Myeloid-Neutrophil-Neutrophil-Neu_3\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	HCAR3 HCAR2 ALPL	1.71e-04	173	28	3	bf685025961e79b379f2c35464b6c8ce3e31ace0
ToppCell	BAL-Severe-Myeloid-Neutrophil\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	HCAR3 HCAR2 ALPL	1.71e-04	173	28	3	a6e73a40b0d5356564a594053e772f9d061a5919
ToppCell	facs-Marrow-KLS-3m-Lymphocytic-immature_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RTN4IP1 PIGR FERMT1	1.71e-04	173	28	3	8bffd512a4e561e23cc04478e2ca6fd5d3771fe4
ToppCell	facs-Marrow-KLS-3m-Lymphocytic-immature_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RTN4IP1 PIGR FERMT1	1.71e-04	173	28	3	3e3c61468e703330788a10d850ef41a85680f86d
ToppCell	BAL-Severe-Myeloid-Neutrophil-Neutrophil\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	HCAR3 HCAR2 ALPL	1.71e-04	173	28	3	a8b5370f4c893a20c58e97659f3ac168699693f8
ToppCell	droplet-Lung-18m-Epithelial-airway_epithelial-club_cell\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	PIGR ALPL FERMT1	1.73e-04	174	28	3	46838b4bb9b4d8ce5e1c608a700e7f393bc52658
ToppCell	droplet-Lung-18m-Epithelial-airway_epithelial-club_cell-club_cell\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	PIGR ALPL FERMT1	1.73e-04	174	28	3	103594eeb600eb5bc9cbf09a65b286b3a3a18cdc
ToppCell	PND10-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte-Pericyte_G2M\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	PLA2R1 RTN4IP1 ETFBKMT	1.76e-04	175	28	3	15c69dd5635c9251c535f1e22467712e9667ae92
ToppCell	CF-Myeloid-Neutrophil\|Myeloid / Disease state, Lineage and Cell class	HCAR3 HCAR2 ALPL	1.76e-04	175	28	3	8020c3a34f77e68e8149f87481fb1dddd2ac675e
ToppCell	TCGA-Cervix-Primary_Tumor-Cervical_Carcinoma-Non-keratinizing_Cervical_Squamous_Cell_Carcinoma\|TCGA-Cervix / Sample_Type by Project: Shred V9	MTA2 HCAR3 HCAR2	1.79e-04	176	28	3	8513c2a05a34453a16bbcf1c11cb34c580133e47
ToppCell	3'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-club_cell-Club_(non-nasal)-Club_(non-nasal)_L.0.4.0.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	HCAR3 RTN4IP1 PIGR	1.82e-04	177	28	3	a235ff4f37a7622216526191efc4832fb8ed6957
ToppCell	Severe_COVID-19-Myeloid-Neutrophil\|Severe_COVID-19 / Disease group,lineage and cell class （2021.01.30）	HCAR3 HCAR2 ALPL	1.82e-04	177	28	3	a6fae376f1beb1df423484d9b1bd1d954ca117af
ToppCell	Severe-Myeloid-Neutrophil\|Severe / Condition, Lineage, Cell class and cell subclass	HCAR3 HCAR2 ALPL	1.85e-04	178	28	3	454313efe59d71e7327b9758efabf2d893e4a8fd
ToppCell	Severe-Myeloid-Neutrophil-\|Severe / Condition, Lineage, Cell class and cell subclass	HCAR3 HCAR2 ALPL	1.85e-04	178	28	3	8618ae891d62bf70fe860ff7bb2d31868961aa13
ToppCell	390C-Epithelial_cells-Epithelial-B_(AT2)\|390C / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.89e-04	179	28	3	466da2bc3bfc534ffe111c8c28ece7a3cfa08051
ToppCell	390C-Epithelial_cells-Epithelial-B_(AT2)-\|390C / Donor, Lineage, Cell class and subclass (all cells)	PIGR ALPL LRRK2	1.89e-04	179	28	3	f4bdebb77d39e63160fbf3a85a340ce4d52b7cfd
ToppCell	AT2_cells-Myositis-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	PIGR ALPL LRRK2	1.95e-04	181	28	3	ed0ea67f0607073aedf153f8d1073b35e46127c3
Computational	Genes upregulated in subsets of cells of a given type within various tumors	PIGR ALPL LRRK2	5.08e-05	50	16	3	GAVISH_3CA_MALIGNANT_METAPROGRAM_31_ALVEOLAR
Computational	Genes upregulated in subsets of cells of a given type within various tumors	PIGR ALPL LRRK2	5.08e-05	50	16	3	GAVISH_3CA_METAPROGRAM_EPITHELIAL_ALVEOLAR
Drug	tetrahydrodeoxycortisol	HCAR3 HCAR2 CYP21A2	6.54e-06	31	27	3	CID000010593
Drug	Niacin	HCAR3 HCAR2	8.11e-06	4	27	2	DB00627
Drug	thiacloprid	HCAR3 HCAR2 MED13	8.68e-06	34	27	3	CID000115224
Drug	acifran	HCAR3 HCAR2	1.35e-05	5	27	2	ctd:C036804
Drug	imidacloprid	HCAR3 HCAR2 ALPL	3.54e-05	54	27	3	CID000086418
Drug	Nicotinic Acids	HCAR3 HCAR2	3.78e-05	8	27	2	ctd:D009539
Drug	acifran	HCAR3 HCAR2	4.85e-05	9	27	2	CID000051576
Drug	CP-690334-01 [459212-38-5]; Up 200; 1uM; MCF7; HT_HG-U133A	MTA2 PIGR ALPL VAMP1	8.32e-05	198	27	4	3909_UP
Drug	isonicotinic acid	HCAR3 HCAR2	8.87e-05	12	27	2	CID000005922
Drug	(-)-pictamine	HCAR3 HCAR2	1.41e-04	15	27	2	CID006918623
Drug	(-)-lepadin B	HCAR3 HCAR2	1.41e-04	15	27	2	CID006918624
Drug	UB-165	HCAR3 HCAR2	1.41e-04	15	27	2	CID004694339
Drug	AC1L2SVN	HCAR3 HCAR2	1.61e-04	16	27	2	CID000127922
Drug	tetramisole	HCAR3 HCAR2 ALPL	2.04e-04	97	27	3	CID000003913
Drug	ABT-594	HCAR3 HCAR2	2.05e-04	18	27	2	CID003075702
Drug	AC1LCVGE	HCAR3 HCAR2	2.05e-04	18	27	2	CID000656712
Drug	isoarecolone	HCAR3 HCAR2	2.29e-04	19	27	2	CID000146970
Drug	beta-erythroidine	HCAR3 HCAR2	2.29e-04	19	27	2	CID000010074
Drug	AC1L9P88	HCAR3 HCAR2	2.29e-04	19	27	2	CID000450860
Drug	perhydrohistrionicotoxin	HCAR3 HCAR2	2.29e-04	19	27	2	CID000107881
Drug	4-(N-maleimido)benzyltrimethylammonium	HCAR3 HCAR2	2.29e-04	19	27	2	CID000162425
Drug	Pyrazoles	HCAR3 HCAR2	2.54e-04	20	27	2	ctd:D011720
Drug	3-(2-azetidinylmethoxy)pyridine	HCAR3 HCAR2	2.54e-04	20	27	2	CID000001962
Drug	AC1Q5HK6	HCAR3 HCAR2 PIGR CYP21A2 ALPL	2.73e-04	501	27	5	CID000003640
Drug	dinotefuran	HCAR3 HCAR2	2.80e-04	21	27	2	CID000197701
Drug	meproadifen	HCAR3 HCAR2	2.80e-04	21	27	2	CID000189752
Drug	clothianidin	HCAR3 HCAR2	3.08e-04	22	27	2	CID000213027
Drug	AR-R17779	HCAR3 HCAR2	3.08e-04	22	27	2	CID005310971
Drug	histrionicotoxin	HCAR3 HCAR2	3.08e-04	22	27	2	CID005282247
Drug	ABT-418	HCAR3 HCAR2	3.37e-04	23	27	2	CID000119380
Drug	AC1L3BL8	HCAR3 HCAR2	3.37e-04	23	27	2	CID000086457
Drug	alpha-conotoxin SI	HCAR3 HCAR2	3.37e-04	23	27	2	CID000163979
Drug	Skpymrfamide	HCAR3 HCAR2	3.37e-04	23	27	2	CID000132661
Drug	alpha-conotoxin ImI	HCAR3 HCAR2	3.37e-04	23	27	2	CID000133011
Drug	CID6325740	HCAR3 HCAR2	3.37e-04	23	27	2	CID006325740
Drug	procyclidine	HCAR3 HCAR2	3.68e-04	24	27	2	CID000004919
Drug	intruder	HCAR3 HCAR2	3.68e-04	24	27	2	CID000213021
Drug	anabaseine	HCAR3 HCAR2	3.68e-04	24	27	2	CID000018985
Drug	anabasine	HCAR3 HCAR2	4.00e-04	25	27	2	CID000002181
Drug	pempidine	HCAR3 HCAR2	4.00e-04	25	27	2	CID000006603
Drug	varenicline	HCAR3 HCAR2	4.00e-04	25	27	2	CID000170361
Drug	benzquinamide	HCAR3 HCAR2	4.32e-04	26	27	2	CID000002342
Drug	beta-eudesmol	HCAR3 HCAR2	4.32e-04	26	27	2	CID000091457
Drug	curarine	HCAR3 HCAR2	4.32e-04	26	27	2	CID000198004
Drug	AC1O0V2G	HCAR3 HCAR2	4.32e-04	26	27	2	CID006102809
Drug	methylcarbamylcholine	HCAR3 HCAR2	4.67e-04	27	27	2	CID000004136
Drug	nornicotine	HCAR3 HCAR2	4.67e-04	27	27	2	CID000000412
Drug	halothane	HCAR3 HCAR2 CYP21A2 ALPL	4.85e-04	314	27	4	CID000003562
Drug	bifemelane	HCAR3 HCAR2	5.39e-04	29	27	2	CID000002377
Drug	bromoacetylcholine bromide	HCAR3 HCAR2	5.39e-04	29	27	2	CID000204966
Drug	cytidine 5'-diphosphocholine	HCAR3 HCAR2 PITPNA	5.85e-04	139	27	3	CID000000291
Drug	AC1L1JK6	HCAR3 HCAR2	6.17e-04	31	27	2	CID000005077
Drug	tropicamide	HCAR3 HCAR2	6.57e-04	32	27	2	CID000005593
Drug	hydroxyphenylacetic acid	CYP21A2 ALPL	6.99e-04	33	27	2	CID000011970
Drug	decamethonium	HCAR3 HCAR2	6.99e-04	33	27	2	CID000002968
Drug	methamidophos	HCAR3 HCAR2	6.99e-04	33	27	2	CID000004096
Drug	cytisine	HCAR3 HCAR2	6.99e-04	33	27	2	CID000010235
Drug	tert-butyl glutaminate	HCAR3 HCAR2	7.42e-04	34	27	2	CID003450458
Drug	GTS-21	HCAR3 HCAR2	7.42e-04	34	27	2	CID005310985
Drug	l-Lobeline	HCAR3 HCAR2	7.42e-04	34	27	2	CID000003945
Drug	atracurium	HCAR3 HCAR2	7.87e-04	35	27	2	CID000047319
Drug	EPTC	HCAR3 HCAR2	7.87e-04	35	27	2	CID000012968
Drug	(+/-)-Epibatidine	HCAR3 HCAR2	7.87e-04	35	27	2	CID000001204
Drug	PhTX-343	HCAR3 HCAR2	8.32e-04	36	27	2	CID000159548
Drug	O585	HCAR3 HCAR2	8.79e-04	37	27	2	CID000107646
Drug	NSC-293162	HCAR3 HCAR2	9.27e-04	38	27	2	CID000004675
Drug	ferric chloride hexahydrate	CYP21A2 ALPL	1.03e-03	40	27	2	CID000024810
Drug	flurbiprofen	MTA2 HCAR3 HCAR2	1.07e-03	171	27	3	CID000003394
Drug	N-methylscopolamine	HCAR3 HCAR2	1.13e-03	42	27	2	CID000004120
Drug	QX-222	HCAR3 HCAR2	1.13e-03	42	27	2	CID000005014
Disease	alkaline phosphatase measurement, liver enzyme measurement	JMJD1C ALPL	1.30e-05	6	28	2	EFO_0004533, EFO_0004582
Disease	Squamous cell carcinoma	HCAR3 HCAR2 TIAM1	2.20e-04	124	28	3	C0007137
Disease	triglyceride measurement, phospholipid measurement	HCAR3 HCAR2 JMJD1C	3.55e-04	146	28	3	EFO_0004530, EFO_0004639
Disease	platelet-to-lymphocyte ratio	PLA2R1 HCAR2 JMJD1C CYP21A2	3.65e-04	363	28	4	EFO_0008446
Disease	Ovarian Mucinous Adenocarcinoma	LRRK2 RPS6KC1	3.97e-04	31	28	2	C1335167
Disease	fibrinogen measurement, tissue plasminogen activator measurement	JMJD1C CYP21A2	8.38e-04	45	28	2	EFO_0004623, EFO_0004791
Disease	fibrinogen measurement, plasminogen activator inhibitor 1 measurement	JMJD1C CYP21A2	8.38e-04	45	28	2	EFO_0004623, EFO_0004792
Disease	low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio	HCAR3 HCAR2 JMJD1C	8.87e-04	200	28	3	EFO_0004611, EFO_0020945
Disease	metabolic syndrome	HCAR3 HCAR2 JMJD1C	8.87e-04	200	28	3	EFO_0000195
Disease	triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement	HCAR3 HCAR2 JMJD1C	1.24e-03	225	28	3	EFO_0008317, EFO_0020947
Disease	Ischemic stroke, fibrinogen measurement	JMJD1C CYP21A2	1.25e-03	55	28	2	EFO_0004623, HP_0002140
Disease	fibrinogen measurement, factor VII measurement	JMJD1C CYP21A2	1.39e-03	58	28	2	EFO_0004619, EFO_0004623
Disease	Skin Neoplasms	HCAR3 HCAR2	1.44e-03	59	28	2	C0037286
Disease	Malignant neoplasm of skin	HCAR3 HCAR2	1.44e-03	59	28	2	C0007114
Disease	cholesteryl esters:total lipids ratio, high density lipoprotein cholesterol measurement	HCAR3 HCAR2 JMJD1C	1.55e-03	243	28	3	EFO_0004612, EFO_0020944
Disease	HDL cholesterol change measurement, physical activity	HCAR3 HCAR2	1.59e-03	62	28	2	EFO_0003940, EFO_0007805
Disease	urinary metabolite measurement	CYP21A2 BSPH1 ALPL	1.59e-03	245	28	3	EFO_0005116
Disease	urolithiasis	CYP21A2 ALPL	1.64e-03	63	28	2	MONDO_0024647
Disease	venous thromboembolism, fibrinogen measurement	JMJD1C CYP21A2	1.85e-03	67	28	2	EFO_0004286, EFO_0004623
Disease	phospholipids:total lipids ratio, intermediate density lipoprotein measurement	JMJD1C CYP21A2	1.85e-03	67	28	2	EFO_0008595, EFO_0020946

Protein segments in the cluster

Peptide	Gene	Start	Entry
KHKHKKLQSFYPWEW	ERVK-19	301	O71037
KHKHKKLQSFYPWEW	ERVK-8	301	Q902F8
SSRKWCWVNYLLKAK	CATSPERE	331	Q5SY80
KHCWLLKTHWTLDKY	FERMT1	66	Q9BQL6
CASCWIYWKKYGGLK	MTA2	391	O94776
CAYKLVTVKFKWWGL	PITPNA	191	Q00169
GTHIKLWKLCYFRWV	MTMR10	651	Q9NXD2
WKRYSDFKKLHKELW	RPS6KC1	51	Q96S38
GLALWIFCFHLKSWK	HCAR2	46	Q8TDS4
WICEKHILWLKDYKN	JMJD1C	2161	Q15652
YKCIQEVLKTWSHWS	CYP21A2	191	P08686
KLFWLEACYKALTWH	LRRK2	346	Q5S007
FGKKCWRKVWALLYA	DOK3	76	Q7L591
KHKHKKLQSFYPWEW	ERVK-7	1061	P63135
CAYKLVTIKFKWWGL	PITPNB	191	P48739
WKSFKPRYKHSHFIW	ALPL	256	P05186
EGKCYWFSTSFKTWK	KLRF2	86	D3W0D1
KLEYLVKWRGWSSKH	CBX2	26	Q14781
HKWCSLNKTYEGYWK	BSPH1	66	Q075Z2
KHKHKKLQSFYPWEW	ERVK-25	301	P61570
KHKHKKLQSFYPWEW	ERVK-6	301	Q69384
WHKKWKEFLGLSPFS	HAUS6	376	Q7Z4H7
KHKHKKLQSFYPWEW	HERVK_113	301	Q902F9
ADSLHQWLKKCFWTY	ETFBKMT	196	Q8IXQ9
PVFKSWIHCWKYLSV	MTCH1	351	Q9NZJ7
SKALKHFWKGVHYRW	RTN4IP1	326	Q8WWV3
SSAAKLKRKYWWKNC	VAMP1	81	P23763
GLALWIFCFHLKSWK	HCAR3	46	P49019
CLADLTGIKWKKYVW	MED13	21	Q9UHV7
SKIKALSKYGASWWI	PLA2R1	861	Q13018
DWKVHKGKCYWIAET	CLECL1	121	Q8IZS7
KGKCYWIAETKKSWN	CLECL1	126	Q8IZS7
KCYSWKKDWYSHVKS	ZBTB11	801	O95625
KWKHYWVSLKGCTLF	TIAM1	461	Q13009
FVLSVHYLWKKWKKH	TEX50	91	A0A1B0GTY4
KESKSIKYWCLWEGA	PIGR	376	P01833